Human Cancer-Associated Mutations in the Aα Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in Aα Knock-In and Knockout Mice
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Strong evidence has indicated that protein phosphatase 2A (PP2A) is a tumor suppressor, but a mouse model for testing the tumor suppressor activity was missing. The most abundant forms of trimeric PP2A holoenzyme consist of the scaffolding Aα subunit, one of several regulatory B subunits, and the catalytic Cα subunit. Aα mutations were discovered in a variety of human carcinomas. All carcinoma-associated mutant Aα subunits are defective in binding the B or B and C subunits. Here we describe two knock-in mice expressing cancer-associated Aα point mutants defective in binding B' subunits, one knockout mouse expressing truncated Aα defective in B and C subunit binding, and a floxed mouse for generating conditional Aα knockouts. We found that the cancer-associated Aα mutations increased the incidence of cancer by 50 to 60% in lungs of FVB mice treated with benzopyrene, demonstrating that PP2A acts as a tumor suppressor. We show that the effect of Aα mutation on cancer incidence is dependent on the tumor suppressor p53. The finding that the Aα mutation E64D, which was detected in a human lung carcinoma, increases the lung cancer incidence in mice suggests that this mutation also played a role in the development of the carcinoma in which it was discovered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, recurrent mutation of these residues (for example, P179, R183, S256, and R258) result in marked changes in the PP2A holoenzyme composition in cells (Haesen et al., 2016; O’Connor et al., 2019; Ruediger et al., 2011; Taylor et al., 2019).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Ruediger et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with the observations from Cα KO mice, constitutive KO of Ppp2r1a in two different models resulted in embryonic lethality between E5 and E10.5 [10,36].”
From Physiologic functions of PP2A: Lessons from genetically modified mice (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in an in vivo knockin model of the cancer-associated E64G Aα mutant, defective in B56α and B56δ (and potentially other B56 isoforms) binding [10,93], there was no impact on retina structure and function.”
From Physiologic functions of PP2A: Lessons from genetically modified mice (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More importantly, knockout (KO) studies in mice have revealed that the homozygous deletion of PPP2R1A and PPP2CA is embryonically lethal [ 36 – 38 ].”
From Targeting PP2A in cancer: an underrated option (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For instance, the Aα E64G and E64D mutants, respectively discovered in breast and lung carcinoma [104], were found to be defective in B56α and B56δ binding in vivo [10], and B56γ binding in vitro [93].”
From Physiologic functions of PP2A: Lessons from genetically modified mice (2019) · cites this paper as [10]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159 · cited 8×
“Conversely, overexpression of B reverts SV40-STdependent transformation (7, 8).”
BackgroundResultInfluentialRetractedRepbase Update, a database of eukaryotic repetitive elements
Jurka, J., Kapitonov, V. V., Pavlicek, A., Klonowski, P., Kohany, O., & Walichiewicz, J. (2005) · Cytogenetic and Genome Research · doi:10.1159/000084979 · Cited by 3,370
Janssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,902 · cited 2×
“Protein phosphatase 2A (PP2A) plays a role in many fundamental cellular processes, such as signal transduction, DNA repair, transcription, translation, and growth control (15, 24, 26, 43, 77).”
BackgroundHayashi, S., & McMahon, A. P. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0597 · Cited by 1,342 · cited 2×
“receptor (ER) that binds tamoxifen (TM) but not endogenous estrogen (21).”
BackgroundFrequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219 · cited 1×
“In a third ovarian cancer, arginine 182 is mutated to tryptophan (27).”
BackgroundA one-step purification of membrane proteins using a high efficiency immunomatrix.
Schneider, C., Newman, R. A., Sutherland, D. R., Asser, U., & Greaves, M. F. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33889-4 · Cited by 764 · cited 1×
“were coupled to monoclonal antibody 6F9 as described previously (60).”
MethodCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 1×
“Further evidence that PP2A is a tumor suppressor comes from the discovery that the B holoenzyme plays a key role in Myc degradation (2) and from the identification of an inhibitor, CIP2A, which binds to PP2A and Myc, thus preventing PP2A from dephosphorylating Myc at serine 62, a prerequisite for Myc degradation (28).”
BackgroundEnumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612 · cited 3×
“An important discovery was that SV40-ST is required for the transformation of primary human cells in combination with SV40 large T antigen, H-ras, and telomerase (20, 80).”
BackgroundWidespread recombinase expression using FLPeR (Flipper) mice
Farley, F. W., Soriano, P., Steffen, L. S., & Dymecki, S. M. (2000) · genesis · doi:10.1002/1526-968x(200011/12)28:3/4<106::aid-gene30>3.0.co;2-t · Cited by 610 · cited 3×
“The CreER mouse was obtained from The Jackson Laboratory (catalog number 004682).”
MethodInfluentialOkadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter.
Suganuma, M., Fujiki, H., Suguri, H., Yoshizawa, S., Hirota, M., Nakayasu, M., Ojika, M., Wakamatsu, K., Yamada, K., & Sugimura, T. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.6.1768 · Cited by 597 · cited 1×
“The first indication that PP2A might be a tumor suppressor came from the finding that okadaic acid is both a tumor promoter and an inhibitor of PP2A (18, 25, 43, 69, 77).”
Background
Cited by
Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore
Foley, E. A., & Kapoor, T. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3494 · Cited by 636
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer
Seshacharyulu, P., Pandey, P., Datta, K., & Batra, S. K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.036 · Cited by 481
“Based on the mutations E64G and E64D, four different mouse strains were developed by Ruediger et al 2011: knock-in models E64D/ + and E64G/+; conditional Aα knock-out F5-6/+ with exon 5 and 6 floxed for Aα allele; and Δ5-6/+ was harboring exon 5 and 6 deletion in the Aα allele.”
BackgroundMethodInfluentialProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Phosphatase PP2A is requisite for the function of regulatory T cells
Apostolidis, S. A., Rodríguez-Rodríguez, N., Suárez-Fueyo, A., Dioufa, N., Ozcan, E., Crispín, J. C., Tsokos, M. G., & Tsokos, G. C. (2016) · Nature Immunology · doi:10.1038/ni.3390 · Cited by 238
Protein Ser/ Thr phosphatases – the ugly ducklings of cell signalling
Brautigan, D. L. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08609.x · Cited by 222
Sents, W., Ivanova, E., Lambrecht, C., Haesen, D., & Janssens, V. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08579.x · Cited by 204
O’Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 190
“…and changes in phosphorylation/methylation of the C subunit (Cristóbal et al., 2015; Ion Cristóbal et al., 2014; Haesen et al., 2016; Janghorban et al., 2014; Liu et al., 2015; Nobumori et al., 2013; Rincón et al., 2015; Ruediger et al., 2011, 2001; Saddoughi et al., 2013; Shouse et al., 2016).”
BackgroundSelective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
“Interestingly, recurrent mutation of these residues (for example, P179, R183, S256, and R258) result in marked changes in the PP2A holoenzyme composition in cells (Haesen et al., 2016; O’Connor et al., 2020; Ruediger et al., 2011; Taylor et al., 2019).”
BackgroundPP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
“Notably, in two independent in vivo lung cancer models, PPP2R1A mutation either increased tumor burden or decreased survival of KRAS-mutant mice (8, 10).”
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
“carcinoma in response to benzopyrene compared to mice with wildtype A alpha subunit expression [164].”
BackgroundStructure, Regulation, and Pharmacological Modulation of PP2A Phosphatases
Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., & Janssens, V. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-562-0_17 · Cited by 140
Xiao, G., Chan, L. N., Klemm, L., Braas, D., Chen, Z., Geng, H., Zhang, Q. C., Aghajanirefah, A., Cosgun, K. N., Sadras, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.048 · Cited by 129
“As a model for loss of PP2A holoenzyme activity, we studied genetic ablation of the Ppp2r1a gene encoding the PP2A scaffold subunit Aa (PP2A Sub A), which is essential for PP2A activity (Ruediger et al., 2011).”
BackgroundPhysiologic functions of PP2A: Lessons from genetically modified mice
Reynhout, S., & Janssens, V. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.010 · Cited by 124
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., Amant, F., Waelkens, E., Sablina, A., & Janssens, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3342 · Cited by 124
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
Clark, A. R., & Ohlmeyer, M. H. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.016 · Cited by 122
Molecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 113
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“A mechanism of haploinsufficiency was found for two non-recurrent cancer-associated PPP2R1A mutations in HEAT-repeat 2 (E64D and E64G) (32), primarily affecting holoenzyme formation with B56γ and preventing suppression of AKT phosphorylation (40-42).”
BackgroundLiu, H., Gu, Y., Wang, H., Yin, J., Zheng, G., Zhang, Z., Lu, M., Wang, C., & He, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3818 · Cited by 95
“Animal studies also showed that PR65α point mutations and deletions increase the incidence of lung cancer [40].”
PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
Lillo, C., Kataya, A. R. A., HEIDARI, B., Creighton, M. T., Nemie-Feyissa, D., Ginbot, Z., & Jonassen, E. M. (2014) · Plant Cell & Environment · doi:10.1111/pce.12364 · Cited by 104
PP2A: The Wolf in Sheep’s Clothing?
Kiely, M., & Kiely, P. (2015) · Cancers · doi:10.3390/cancers7020648 · Cited by 78
“Mice expressing the E64D mutation demonstrated increased incidence of p53 dependant lung cancer [40].”
The basic biology of PP2A in hematologic cells and malignancies
Haesen, D., Sents, W., Lemaire, K., Hoorne, Y., & Janssens, V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00347 · Cited by 73
Hein, A. L., Seshacharyulu, P., Rachagani, S., Sheinin, Y. M., Ouellette, M. M., Ponnusamy, M. P., Mumby, M. C., Batra, S. K., & Yan, Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2119 · Cited by 66
“Consistently, two cancer-related PP2A-Aα point mutants, E64G in breast cancer and E64D in lung cancer, are defective in binding to PR61, but can bind normally to PR55α (44,45).”
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65
Shamay, M., Liu, J., Li, R., Liao, G., Li, S., Greenway, M., Hu, S., Zhu, J. K., Xie, Z., Ambinder, R. F., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00169-12 · Cited by 63
Reynhout, S., Jansen, S., Haesen, D., Belle, S. V., de Munnik, S. A., Bongers, E. M. H. F., Schieving, J., Marcelis, C., Amiel, J., Rio, M., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.12.002 · Cited by 67
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
Remmerie, M., & Janssens, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00462 · Cited by 64
Gordon, I. K., Lu, J., Graves, C. A., Huntoon, K. M., Frerich, J. M., Hanson, R., Wang, X., Hong, C. S., Ho, W. S., Feldman, M. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0614 · Cited by 64
“PP2A is a tumor suppressor, and its function can be lost by inactivating mutations of structural subunits or up-regulation of cellular PP2A inhibitors (4-7).”
Bai, X., Zhi, X., Zhang, Q., Liang, F., Chen, W., Liang, C., Hu, Q., Sun, X., Zhuang, Z., & Liang, T. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.048 · Cited by 58
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
Remmerie, M., & Janssens, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082380 · Cited by 57
Chen, S., Chen, L., Ye, L., Jiang, Y., Li, Q., Zhang, H., Zhang, R., Li, H., Yu, D., Zhang, R., et al. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.127624 · Cited by 61
Raman, D., & Pervaiz, S. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101105 · Cited by 59
“substitutions, result in the inability of the scaffold subunit to bind the regulatory B56α and B56δ subunits of PP2A, respectively [76,77].”
BackgroundLoss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo
Lambrecht, C., Libbrecht, L., Sagaert, X., Pauwels, P., Hoorne, Y., Crowther, J., Louis, J. V., Sents, W., Sablina, A., & Janssens, V (2018) · Oncogene · doi:10.1038/onc.2017.350 · Cited by 50
Lv, P., Wang, Y., Ma, J., Wang, Z., Li, J.-L., Hong, C. S., Zhuang, Z., & Zeng, Y.-X. (2014) · Oncotarget · doi:10.18632/oncotarget.2258 · Cited by 52
“PP2A is a tumor suppressor and its function can be reduced by inactivating mutations of structural subunits or by up-regulation of cellular PP2A inhibitors [8-11].”
BackgroundRetractedSmith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., Panicker, N., Mashkani, B., Don, A. S., Morris, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10167 · Cited by 51
“PP2A-A knockdown has been shown to induce a concomitant loss of PP2A-B55, -B56α and –B56δ subunit proteins, and reduced PP2A activity [48, 49], therefore, the decreased PP2A-A may also contribute to the downregulation of PP2A-B subunits we observed in the FLT3-ITD cells.”
BackgroundScaffold Subunit Aalpha of PP2A Is Essential for Female Meiosis and Fertility in Mice1
Hu, M.-W., Wang, Z.-B., Jiang, Z.-Z., Qi, S.-T., Huang, L., Liang, Q.-X., Schatten, H., & Sun, Q.-Y. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.114.120220 · Cited by 48
Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options
Grech, G., Baldacchino, S., Saliba, C., Grixti, M. P., Gauci, R., Magri, V. P., Fenech, A. G., & Scerri, C. A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5145-4 · Cited by 54
“The mechanism of PP2A inhibition by CIP2A is not well annotated although some suggest that CIP2A binds to PP2Ac allosterically at its B subunit binding interface, thus altering substrate specificity and/or limiting activity [32, 36, 51, 56].”
BackgroundInactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors
O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene · doi:10.1038/s41388-019-1012-2 · Cited by 48
“Given that studies have shown that PP2A Aα mutations result in altered holoenzyme complex formation and Aα interactome [16, 19, 20], we first used co-immunoprecipitation of V5tagged WT or R183W Aα protein in our cell models, SW620 and M/R cells, followed by mass spectrometry analysis (AP-MS) to determine the effect of…”
BackgroundMethodBaldacchino, S., Saliba, C., Petroni, V., Fenech, A. G., Borg, N., & Grech, G. (2014) · EPMA Journal · doi:10.1186/1878-5085-5-3 · Cited by 44
“Loss of heterozygosity is observed in a significant percentage of breast, lung, ovarian, colon and liver and melanoma malignancies and to a lesser extent in non-Hodgkin’s lymphomas and chronic lymphocytic leukaemia [15-20].”
BackgroundNader, C. P., Cidem, A., Verrills, N. M., & Ammit, A. J. (2019) · Respiratory Research · doi:10.1186/s12931-019-1192-x · Cited by 42
“These findings further suggest that the functional PP2A holoenzyme is important in tumour suppression and PP2A-Aα subunit mutations may play an essential role in tumourigenesis of the lung [50, 54].”
Pandey, P., Seshacharyulu, P., Das, S., Rachagani, S., Ponnusamy, M. P., Yan, Y., Johansson, S. L., Datta, K., Fong Lin, M., & Batra, S. K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.160 · Cited by 39
“In addition, the direct evidence of PP2A as a tumour suppressor has been shown in a knock-in and knockout mouse model expressing E64D and E64G mutations (Ruediger et al, 2011).”
BackgroundWalter, G., & Ruediger, R. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19057 · Cited by 37
Self-citationBiased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules
Haanen, T. J., O’Connor, C. M., & Narla, G. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102656 · Cited by 42
“Additional studies found that SMAPs impaired tumor growth in multiple different cancer types including Burkitt’s lymphoma, pancreatic ductal adenocarcinoma, lung, and breast cancer that are driven by different oncogenes like KRAS and MYC, suggesting that PP2A reactivation may be effective for the treatment of a broad…”
BackgroundInfluentialHow it all Started: Tau and Protein Phosphatase 2A
Liu, C., & Götz, J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130503 · Cited by 45
“A knock-out of the structural subunit A in mice confirmed that PP2A acts as a tumor suppressor [69].”
BackgroundPpp2ca knockout in mice spermatogenesis
Pan, X., Chen, X., Tong, X., Tang, C., & Li, J. (2015) · Reproduction · doi:10.1530/rep-14-0231 · Cited by 32
Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis
Chen, L., Guo, P., Li, W., Fang, F., Zhu, W., Fan, J., Wang, F., Gao, Y., Zhao, Q., Wang, Q., et al. (2020) · Hepatology · doi:10.1002/hep.31457 · Cited by 32
“(14) The stability of PP2A AC dimer is essential for cell survival,(37) and lacking the PP2A Aα subunit leads to embryo lethality in animals.(38) Exceeding our expectations, we here failed to observe a dramatic decline in PP2A Cα in conditional Aα gene knockout HO mice.”
Functional importance of PP2A regulatory subunit loss in breast cancer
Watt, L. F., Panicker, N., Mannan, A., Copeland, B., Kahl, R. G. S., Dun, M. D., Young, B., Roselli, S., & Verrills, N. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4403-5 · Cited by 29
Lyons, S. P., Jenkins, N. P., Nasa, I., Choy, M. S., Adamo, M. E., Page, R., Peti, W., Moorhead, G. B. G., & Kettenbach, A. N. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000822 · Cited by 29
Panicker, N., Coutman, M., Lawlor-O’Neill, C., Kahl, R. G. S., Roselli, S., & Verrills, N. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00358 · Cited by 28
Kurimchak, A., & Graña, X. (2012) · Genes & Cancer · doi:10.1177/1947601912473479 · Cited by 33
“These mice were around 60% more susceptible to lung tumors than their wild-type counterparts when treated with benzopyrene.(56,57) Together, these studies strongly suggest that the 2 genes (PPP2R1A and PPP2R1B) encoding PP2A/A scaffolding subunits are haploinsufficient tumor suppressors.”
BackgroundWang, H., Xu, K., Wang, B., Liu, J., Wang, X., Xing, M., Huang, P., Guo, Z., & Xu, L. (2016) · Environmental Toxicology · doi:10.1002/tox.22305 · Cited by 27
“Disruptions in PP2A assembly, activity, and substrate specificity have been observed to contribute to the maintenance of the transformed phenotype in cancer, including lung carcinoma (Ruediger et al., 2011; Khanna et al., 2013; Pandey et al., 2013; Stebbing et al., 2014).”
BackgroundNeale, D. B., Morris, J. C., Verrills, N. M., & Ammit, A. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108834 · Cited by 28
Cellular inhibitors of Protein Phosphatase PP2A in cancer.
Haesen, D., Sents, W., Ivanova, E., Lambrecht, C., & Janssens, V. (2012) · Lirias · Cited by 33
Yen, Y., Chien, M., Wu, P., & Hung, S. (2021) · Communications Biology · doi:10.1038/s42003-021-02175-1 · Cited by 25
Hong, J. H., Cho, H., Ouh, Y., Lee, J. K., Chun, Y., & Gim, J. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e29 · Cited by 26
“PP2A is involved in a variety of cellular pathways such as cell growth and survival and has been implicated as a tumor suppressor [23].”
BackgroundProtein Phosphatase 6 Protects Prophase I-Arrested Oocytes by Safeguarding Genomic Integrity
Hu, M., Meng, T., Jiang, Z., Dong, M., Schatten, H., Xu, X., Wang, Z., & Sun, Q. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006513 · Cited by 23
Protein phosphatase 6 is a key factor regulating spermatogenesis
Lei, W., Han, F., Hu, M., Liang, Q., Meng, T., Zhou, Q., Ouyang, Y., Hou, Y., Schatten, H., Wang, Z., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0472-9 · Cited by 23
“PP2A is involved in cell proliferation, signal transduction, DNA repair, and apoptosis [12].”
BackgroundInterplay between Phosphatases and the Anaphase-Promoting Complex/Cyclosome in Mitosis
Kataria, M., & Yamano, H. (2019) · Cells · doi:10.3390/cells8080814 · Cited by 28
“Cancer-associated mutations within the scaffolding [268,269], catalytic [270] and regulatory subunits [271] typically tend to affect assembly of the holoenzyme.”
BackgroundProtective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
Advani, D., Gupta, R. V., Tripathi, R. S., Sharma, S., Ambasta, R. K., & Kumar, P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104841 · Cited by 25
PPP2R1B is modulated by ubiquitination and is essential for spermatogenesis
Du, M., Yuan, L., Zhang, Z., Zhang, C., Zhu, M., Zhang, Z., Li, R., Zhao, X., Liang, H., Li, Y., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002810r · Cited by 20
Hu, M., Wang, Z., Teng, Y., Jiang, Z., Ma, X., Hou, N., Cheng, X., Schatten, H., Xu, X., Yang, X. Y., et al. (2015) · Journal of Cell Science · doi:10.1242/jcs.173179 · Cited by 26
“PP2A is involved in regulating chromosome condensation, DNA damage repair, the G2/M transition and sister chromatid cohesion (Ruediger et al., 2011).”
BackgroundProtein phosphatase 2A in the healthy and failing heart: New insights and therapeutic opportunities
Sergienko, N. M., Donner, D. G., Delbridge, L. M. D., McMullen, J. R., & Weeks, K. L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110213 · Cited by 20
Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis
Christianson, D. R., Dobroff, A. S., Proneth, B., Zurita, A. J., Salameh, A., Dondossola, E., Makino, J., Bologa, C., Smith, T. L., Yao, V. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424994112 · Cited by 19
“Because loss of PPP2R1A in mice is lethal, at least a minimal amount of PPP2R1A is required to maintain cell viability (31, 32).”
BackgroundCD25 and Protein Phosphatase 2A Cooperate to Enhance IL-2R Signaling in Human Regulatory T Cells
Ding, Y., Yu, A., Tsokos, G. C., & Malek, T. R. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801570 · Cited by 18
“Ppp2r1a mice carrying the loxP sites across exons 5–6 of Ppp2r1a (strain: 017441) (19) and Foxp3 mice expressing yellow fluorescent protein (YFP) and Cre recombinase via the Tregspecific gene Foxp3 (strain: 016959) (20) were obtained from The Jackson Laboratory.”
MethodProtein phosphatase 2A Aα regulates Aβ protein expression and stability
O’Connor, C. M., Hoffa, M. T., Taylor, S. E., Avelar, R. A., & Narla, G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007593 · Cited by 15
Kolesnikov, A. V., Orban, T., Jin, H., Brooks, C., Hofmann, L., Dong, Z., Sokolov, M., Palczewski, K., & Kefalov, V. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712405114 · Cited by 16
“Previous attempts at understanding the involvement of PP2A in the dephosphorylation of GPCRs have failed due to its embryonic lethality in mice with conventional knockout of its dominant catalytic subunit PP2A-Cα (26) or its major scaffolding subunit PP2A-Aα (27).”
BackgroundMacKay, K. B., Tu, Y., Young, S. G., & Clarke, S. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065967 · Cited by 14
PP2A Phosphatase as an Emerging Viral Host Factor
Barski, M. S., Minnell, J. J., & Maertens, G. N. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.725615 · Cited by 14
Meeusen, B., Cortesi, E. E., Omella, J. D., Sablina, A. A., Ventura, J., & Janssens, V. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.022 · Cited by 14
Shomin-Levi, H., & Yarden, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01694 · Cited by 15
“This has been demonstrated both in mammalian as well as fungal systems, including in N. crassa (Yang et al., 2004; Ruediger et al., 2011; Seshacharyulu et al., 2013).”
BackgroundAllosteric activation of PP2A inhibits experimental abdominal aortic aneurysm
Zhou, X., Zhang, C., Xie, F., Wei, W., Li, R., Xu, Q., Wang, Y., Klenotic, P. A., Narla, G., Dong, N., et al. (2021) · Clinical Science · doi:10.1042/cs20210315 · Cited by 10
PPP2R1A neurodevelopmental disorder is associated with congenital heart defects
Baker, E. K., Solivio, B., Pode‐Shakked, B., Cross, L., Sullivan, B. R., Raas‐Rothschild, A., Chorin, O., Barel, O., Bar‐Yosef, O., Husami, A., et al. (2022) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62946 · Cited by 11
“Mice homozygous for a null PPP2R1A allele have early lethality which reinforces the importance of this gene in development (Ruediger et al., 2011).”
BackgroundBanerjee, A., Mathew, S., Naqvi, M. M., Yilmaz, S. Z., Zacharopoulou, M., Doruker, P., Kumita, J. R., Yang, S.-H., Gür, M., Itzhaki, L. S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn2208 · Cited by 13
Ding, J., Wang, Y., Huang, J. A., Lian, Y., Meng, Y., Li, C., He, Y., & Qiu, P. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001495 · Cited by 10
Sule, A. D., Golding, S. E., Ahmad, S. F., Watson, J., Ahmed, M. H., Kellogg, G. E., Bernaś, T., Koebley, S. R., Reed, J. C., Povirk, L. F., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04550-5 · Cited by 10
“PR65flox/E64G MEFs express a known human tumor-associated PR65 mutant [32], constructed the same as S401A and S401D MEFs, and here used as control cells expressing mutant PR65.”
InfluentialRules for PP2A-controlled phosphosignalling and drug responsesPreprint
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Laajala, T. D., Yetukuri, L., Laine, A., Jumppanen, M., Haapaniemi, P., Ruan, L., Yadav, B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/271841 · Cited by 11
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
“Guidelines for the nomenclature-del: deletion; fs: frameshift; splice: RNA splicing/splice variant; *: stop codon ) [36] Weight loss and death on day 6 Aα cKO (O) [138] ↑ Aneuploidy Subfertility Chromosome segregation Aα cKO (T-cells) [139] ↑ Autoimmunity ↑ Effector immune response ↑ mTORC1 Aα cKO…”
Linxweiler, J., Kollipara, L., Zahedi, R. P., Lampel, P., Zimmermann, R., & Greiner, M. (2014) · EuPA Open Proteomics · doi:10.1016/j.euprot.2014.05.004 · Cited by 8
“Additionally, PP2A mutations reportedly increase the incidence of lung cancer in mice [30].”
BackgroundDevelopmental and light regulation of tumor suppressor protein PP2A in the retina
Rajala, A., Wang, Y., Abcouwer, S. F., Gardner, T. W., & Rajala, R. V. S. (2018) · Oncotarget · doi:10.18632/oncotarget.23351 · Cited by 7
“PP2A has been identified as a tumor suppressor for blood cancers, and mutations in the Aαsubunit (E64D) increased the incidence of cancers due to the lack of tumor-suppressing phosphatase activity [4].”
BackgroundInfluentialProtein Phosphatase Signaling in Cardiac Myocytes
Abdallah, D., Malhotra, N., & Refaey, M. E. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_5 · Cited by 6
Cellular protrusions in 3D: Orchestrating early mouse embryogenesis
Omelchenko, T. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.05.005 · Cited by 6
Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases
Yu, H. K. Y., Zaveri, S., Sattar, Z., Schaible, M., Gandara, B. P., Uddin, A., McGarvey, L. R., Ohlmeyer, M. H. J., & Geraghty, P. M. (2023) · Medicina · doi:10.3390/medicina59091552 · Cited by 5
“Particularly, mutations in the PP2A-A α subunit correlate with lung cancer (LC), occurring in 1.3% of LC tumors [99].”
BackgroundInfluentialGermline mutations in PPP2R1B in patients with a personal and family history of cancer
Mazhar, S., O’Connor, C. M., Harold, A., Dowdican, A. C., Ulintz, P., Hanson, E. N., Zhang, Y., Jacobs, M. F., Merajver, S. D., Jackson, M. W., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.186288 · Cited by 4
Houge, G., Douzgou, S., Hsieh, T., Verbinnen, I., & Janssens, V. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-025-01901-1 · Cited by 4
Ser/Thr Phosphatases: The New Frontier for Myeloid Leukemia Therapy?
Amanda, M., Kathryn, G., & Nicole, M. (2011) · InTech eBooks · doi:10.5772/26425 · Cited by 5
CIP2A expression predicts recurrences of tamoxifen-treated breast cancer
Baldacchino, S., Wastall, L. M., Saliba, C., Hughes, T. A., Scerri, C. A., Berwick, A., Speirs, V., Hanby, A. M., & Grech, G. (2017) · Tumor Biology · doi:10.1177/1010428317722064 · Cited by 5
Structural and functional studies of proteins in cell signaling and cancer
Dovega, R. (2014) · Figshare · Cited by 2
Uterine secretome: What do the proteins say about maternal-fetal communication in buffaloes?
Codognoto, V. M., de Souza, F. F., Cataldi, T. R., Labate, C. A., de Camargo, L. S., Scott, C., Filho, R. R. D. R., Carvalho, N. A. T., & Oba, E. (2023) · Journal of Proteomics · doi:10.1016/j.jprot.2023.105023 · Cited by 1
Yilmaz, S. Z., Banerjee, A., Saha, S., Ohlmeyer, M. H. J., Gordon, R., Itzhaki, L. S., Bahar, İ., & Gür, M. (2026) · JACS Au · doi:10.1021/jacsau.5c01514 · Cited by 1
Roldán, M., Nolasco, G. A., Armengol, L., Frías, M., Morell, M., García‐Aragonés, M., Epifani, F., Muchart, J., Ramírez-Almaraz, M. L., Martorell, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813699 · Cited by 1
SLMAP3 is crucial for organogenesis through mechanisms involving primary cilia formation
Dias, A. P., Rehmani, T., Applin, B. D., Salih, M., & Tuana, B. S. (2024) · Open Biology · doi:10.1098/rsob.240206 · Cited by 1
“The importance of STRIPAK in mammals is further evidenced by the deficiency of many of its components resulting in mouse embryonic lethality, as observed in the case of PP2A-C [25,26], PP2A-A [27,28], MAP4K4 [29], STRN [30], STRN3 [31,32], STRIP1 [33], Mob4 [34], CCM3 [35,36] and FGFR1OP2 [37].”
BackgroundYu, E. W. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737780632.793574081
Ji, W., Zheng, B., & Zhang, A. (2024) · Clinical Genetics · doi:10.1111/cge.14617 · Cited by 1
“28 In 2015, Houge et al. 27 reported the germline variants of PP2A-coding genes ( PPP2R5D , PPP2R1A , and PPP2CA ) for the first time.”
Cell penetrating and interfering peptides as new cancer therapy
Zhang, X. (2017) · theses.fr (ABES) · doi:10.70675/b2053021ze747z4f1azacb7z8a87a14ec9e3
Liu, Y., Wang, Y., Zhou, H., Wang, Q., Qu, Y., Du, J., Jiang, W., Chen, K., Wu, X., Geng, D., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154189
Metadata
- Authors
- Ruediger, R., Ruiz, J., & Walter, G.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Walter, Gernot
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-09
- Volume
- 31
- Issue
- 18
- Pages
- 3832-3844
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3165721
- OpenAlex
- W2121528020
- Cited by
- 98
- References
- 86
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 7 · 2014: 8 · 2013: 6 · 2012: 7
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tobacco-Related Disease Research Program
- U.S. Public Health Service
- University of California, San Diego
- National Cancer Institute (R01CA118015)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- protein phosphatase 2A, tumor suppressor, lung cancer, cancer-associated mutations, benzopyrene, p53, knock-in mice, knockout mice, floxed mice, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Animals, Base Sequence, Benzopyrenes, Disease Models, Animal, Humans, Lung Neoplasms, Mice, Transgenic, Mutation, Incidence, Tumor Suppressor Protein p53, Point Mutation, Sequence Analysis, DNA, Mice, Knockout, Protein Isoforms, Protein Subunits, Tumor Suppressor Proteins, Mice, Protein Phosphatase 2, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.